Clinical trials: Gastrointestinal Hormones
Esophageal Neoplasms, Stomach Neoplasms
The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
Improvements to treatment strategies for patients with cancers of the upper gastrointestinal tract have produced a large population of people who remain free from cancer recurrence in the long term following treatment.
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Weight Loss, Malnutrition
- Trial name
- NCT02381249
- Testing
- Octreotide
- Where
- 2 sites in Ireland, Sweden
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- St. James's Hospital, Ireland
Healthy
Satiety, Glycemic, and Gastrointestinal Effects of Novel Fibers
Research suggests dietary fiber may play a role in weight management, and fiber consumption is inversely associated with body weight, body fat, and BMI in cross-sectional studies.
- Trial name
- NCT00958399
- Testing
- Resistant Starch, Resistant starch + soluble fiber, Fiber made from corn starch
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Obesity, Liver Diseases
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting…
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat
- Trial name
- NCT06138821
- Testing
- ESG + lifestyle modification, Lifestyle modification
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Pichamol Jirapinyo, MD, MPH
Rectal Cancer
Sexual Function and Wellbeing in Males With Rectal Cancer
Preoperative radiotherapy and pelvic surgery is recommended to many patients with rectal cancer. For men there are theoretical reasons to believe that the treatment may effect hormone levels, spermatogenesis, sexual function and…
- Trial name
- NCT01216202
- Testing
- Preoperative radiotherapy
- Where
- 2 sites in Sweden
- Volunteers
- 178 people
- Sponsor
- Karolinska Institutet
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Gastric Cancer, Oesophageal Cancer
Anorexia iN Cancer Patients: ANCHOR
The rationale for this study is to prospectively investigate the outcomes of patients undergoing standard dietetic interventions alongside treatment for their advanced gastrointestinal cancers, and to further characterise the…
- Trial name
- ANCHOR (NCT04791254)
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- The Christie NHS Foundation Trust
Neuroendocrine Tumors, Neuroendocrine Carcinoma
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms
This study evaluates the possibility and the safety of performing local therapy for Pancreatic neuroendocrine neoplasms (PanNENs) using radiofrequency ablation of the tumor under ultrasonography (EUS) guidance.
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Carcinoma, Pancreas Neoplasm, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
- Trial name
- RAPNEN (NCT03834701)
- Testing
- EUS guided radiofrequency ablation
- Where
- 2 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Catholic University of the Sacred Heart
Sensitivity (Hyper); Gastrointestinal
The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Sensitivity in Healthy Volunteers
Introduction and aim Stress is well known to affect visceral sensitivity in Human. The investigators speculate that visceral hypersensitivity plays an important role in symptom perception in gastro-esophageal reflux disease…
- Trial name
- CRH (NCT02674256)
- Testing
- CRH
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or…
- Conditions
- Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer
- Trial name
- NCT02567396
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib
- Sponsor
- National Cancer Institute (NCI)
Obesity
Effect of Quinine Hydrochloride in Overweight Population on Food Intake, Hunger and Gut Peptide Release
The worldwide increase in the prevalence of obesity is a cause of great concern. Pharmacological treatment options are being explored at the moment with a major focus on the hormones produced by the gastrointestinal tract which…
- Trial name
- NCT04873011
- Testing
- Quinine Hydrochloride
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Obesity, Endoscopic Sleeve Gastroplasty
Endoscopic Sleeve Gastroplasty for Obesity and Microbiota Randomized Trial
This is an interventional, open-label, randomized (2:1), standard medical therapy-controlled trial. Subjects in the standard therapy group will be given the opportunity to undergo the active endoscopic treatment after 6 months of…
- Conditions
- Obesity, Endoscopic Sleeve Gastroplasty, Gastric Motility, Gastric Hormones
- Trial name
- ESGORT (NCT04200144)
- Testing
- Endoscopic sleeve gastroplasty
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Solid Tumor, Solid Tumor, Adult
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of…
- Conditions
- Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor
- Trial name
- NCT06264921
- Testing
- NKT3447
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- NiKang Therapeutics, Inc.
Cirrhosis, Liver
Growth Hormone Therapy in Liver Cirrhosis
Liver cirrhosis (LC) is a leading cause of morbidity and mortality worldwide. Life- threatening complications of liver cirrhosis are ascites, gastrointestinal bleeding, variceal bleed, hepatic encephalopathy and hepatocellular…
- Trial name
- NCT03420144
- Testing
- Standard Medical Therapy, Growth Hormone
- Where
- India
- Volunteers
- 76 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Gastroparesis
Growth Hormone for the Treatment of Gastroparesis
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
- Trial name
- NCT06803589
- Testing
- Growth Hormone
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Obesity, Morbid, Metabolic Syndrome
Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach
Variable outcomes after weight loss surgery are likely attributable to complex, poorly understood mechanisms. Due to the significant impact that morbid obesity has on a patient's health, successful management of obesity and its…
- Conditions
- Obesity, Morbid, Metabolic Syndrome, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT04841057
- Testing
- 50 cm BP limb length, 100 cm BP limb length, 150 cm BP limb length
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Bipolar Depression
Medication, Weight Gain and GI Hormones
This is an 8 week study that compares two medications. One medication is olanzapine (5-20 mg daily) whereas the other medication is an orally disintegrating medication.
- Trial name
- NCT00384332
- Testing
- orally-disintegrating olanzapine, regular olanzapine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Stomach Neoplasm, Chronic Atrophic Gastritis
The Gastric HormonE BioMarkers of Preneoplastic Lesions Study
The goal of the study is to understand whether blood levels of hormones produced or metabolized in the stomach reflect the health of the stomach lining.
- Conditions
- Stomach Neoplasm, Chronic Atrophic Gastritis, Intestinal Metaplasia
- Trial name
- GEM (NCT06085677)
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Liver Cirrhosis
Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis
Phase 1 study of the effects of nitric oxide inhibition with L-NMMA in patients with liver cirrhosis and healthy controls. It is hypothesized that nitric oxide availability is increased in liver cirrhosis.
- Trial name
- NCT00344916
- Testing
- Ng-monomethyl-L-arginine (drug)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Regional Hospital Holstebro
Esophageal Neoplasms, Stomach Neoplasms
Longitudinal Assessment of Gut Hormone Secretion Following Upper Gastrointestinal Surgery for Cancer
Surgery is the cornerstone of treatment for patients with oesophageal or gastric cancer, but while surgical removal of the tumour (oesophagectomy or gastrectomy) may offer the best chance of cure, these are major operations…
- Conditions
- Esophageal Neoplasms, Stomach Neoplasms, Weight Loss, Malnutrition
- Trial name
- NCT02385630
- Testing
- Standardized 400kcal semi-liquid meal
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- St. James's Hospital, Ireland
Neoplasm Malignant, Renal Cell Carcinoma
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination…
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- STELLAR-001 (NCT03845166)
- Testing
- XL092, Atezolizumab, Avelumab
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 325 people
- Sponsor
- Exelixis